Streetbeat News

UNCY

Unicycive Therapeutics, Inc.

https://www.unicycive.com

Industry

Biotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has reiterated its Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 4:12 pm

Unicycive Therapeutics announced favorable results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal trial, highlighting its tolerability and safety. The company plans to submit a New Drug Application in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:32 am

12 health care stocks experienced significant movements in Tuesday's after-market session. Notable gainers include Autonomix Medical (AMIX), Unicycive Therapeutics (UNCY), and Venus Concept (VERO). Significant losers include Calidi Biotherapeutics (CLDI), BioSig Technologies (BSGM), and ThermoGenesis Holdings (THMO).

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 8:31 pm

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:59 pm

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 3:09 pm

HC Wainwright & Co. has reiterated its Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 10:53 am

The article highlights the performance of 12 healthcare stocks during Tuesday's after-market session. Notable gainers include Reshape Lifesciences (RSLS), Dermata Therapeutics (DRMA), and Shuttle Pharmaceuticals (SHPH). Significant losers include Sharecare (SHCR), Reneo Pharmaceuticals (RPHM), and Sharps Technology (STSS).

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 8:31 pm

Unicycive Therapeutics presented data on its kidney disease therapies, oxylanthanum carbonate (OLC) and UNI-494, at the European Renal Association Congress. OLC showed potency in treating hyperphosphatemia, while UNI-494 showed promise in preventing delayed graft function related to acute kidney injury.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:09 am

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Sharps Technology (STSS) saw the highest gain with a 56.5% increase, while TransCode Therapeutics (RNAZ) experienced the largest decline, falling by 13.2%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 8:31 pm

Unicycive Therapeutics announced the presentation of two posters related to its lead product candidate, Oxylanthanum Carbonate, at the National Kidney Foundation Spring Clinical Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.